JP2004515222A - ヒトキニノゲンｄ５ドメインポリペプチドおよびこれらの使用 - Google Patents

ヒトキニノゲンｄ５ドメインポリペプチドおよびこれらの使用 Download PDF

Info

Publication number
JP2004515222A
JP2004515222A JP2002519506A JP2002519506A JP2004515222A JP 2004515222 A JP2004515222 A JP 2004515222A JP 2002519506 A JP2002519506 A JP 2002519506A JP 2002519506 A JP2002519506 A JP 2002519506A JP 2004515222 A JP2004515222 A JP 2004515222A
Authority
JP
Japan
Prior art keywords
polypeptide
cells
tumor
cell
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002519506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004515222A5 (fr
Inventor
アンドリュー ピー． マザール，
ホセ シー． フアレズ，
Original Assignee
アテニュオン， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アテニュオン， エルエルシー filed Critical アテニュオン， エルエルシー
Publication of JP2004515222A publication Critical patent/JP2004515222A/ja
Publication of JP2004515222A5 publication Critical patent/JP2004515222A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
JP2002519506A 2000-07-24 2001-07-24 ヒトキニノゲンｄ５ドメインポリペプチドおよびこれらの使用 Withdrawn JP2004515222A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22019400P 2000-07-24 2000-07-24
PCT/US2001/023185 WO2002014369A2 (fr) 2000-07-24 2001-07-24 Polypeptides du domaine d5 humain de production de kinine s

Publications (2)

Publication Number Publication Date
JP2004515222A true JP2004515222A (ja) 2004-05-27
JP2004515222A5 JP2004515222A5 (fr) 2005-12-22

Family

ID=22822460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002519506A Withdrawn JP2004515222A (ja) 2000-07-24 2001-07-24 ヒトキニノゲンｄ５ドメインポリペプチドおよびこれらの使用

Country Status (4)

Country Link
EP (1) EP1305342A2 (fr)
JP (1) JP2004515222A (fr)
AU (1) AU2001277119A1 (fr)
WO (1) WO2002014369A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1357930B1 (fr) 2001-02-05 2005-11-02 Innoventus Project AB Histidine-rich glycoprotein (hrgp) pour l'inhbition de l'angiogenese
AU2012201537B2 (en) * 2002-07-15 2014-06-05 Board Of Regents, The University Of Texas System Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer
US7378386B2 (en) 2002-07-15 2008-05-27 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
GB0821721D0 (en) * 2008-11-27 2008-12-31 Hansa Medical Ab Antimicrobial therapy
WO2014194259A1 (fr) * 2013-05-30 2014-12-04 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Procédés et compositions pour traiter des maladies cérébrales
US10696728B2 (en) 2014-07-03 2020-06-30 Chunlei Liu Polypeptides, related nucleic acids, and their uses for cell modulation and treatments

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ511488A (en) * 1998-10-16 2003-10-31 Immunex Corp Inhibitors of platelet activation and recruitment comprising an Ala residue and heterologous peptides capable of forming a stable secondary structure attached to a CD39 polypeptide
EP1137659A4 (fr) * 1998-11-10 2005-08-10 Univ Temple Inhibition de l'angiogenese par du kininogene de poids moleculaire eleve et analogues peptidiques dudit kininogene

Also Published As

Publication number Publication date
WO2002014369A9 (fr) 2003-04-03
EP1305342A2 (fr) 2003-05-02
WO2002014369A2 (fr) 2002-02-21
WO2002014369A3 (fr) 2002-09-12
AU2001277119A1 (en) 2002-02-25

Similar Documents

Publication Publication Date Title
US7807621B2 (en) Anti-invasive and anti-angiogenic compositions
JP3880593B2 (ja) アンジオスタチンおよび血管形成の抑制におけるその使用
JP3787157B2 (ja) アンジオスタチンフラグメント、アンジオスタチン凝集体および使用方法
JP2004519215A (ja) クローディンポリペプチド
JP2000509993A (ja) アポリポタンパク質ｂ―１００由来の抗凝血性ペプチド断片
JPH04503761A (ja) Ｐａｉ―２の変異体
KR20010072825A (ko) 안지오시딘: Ｃｙｓ-Ｓｅｒ-Ｖａｌ-Ｔｈｒ-Ｃｙｓ-Ｇｌｙ서열 특이적인 종양 세포 부착 수용체
JP2004515222A (ja) ヒトキニノゲンｄ５ドメインポリペプチドおよびこれらの使用
JP2852192B2 (ja) ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体
US20050124794A1 (en) Cell surface tropomyosin as a target of angiogenesis inhibition
US20140342990A1 (en) Maspin-based treatment and prevention of cancer
JP2006527192A (ja) 血管内皮増殖因子融合構築物およびその使用方法
US20060153831A1 (en) Antithrombosis enzyme from the snake venom of Agkistrodon acutus
US20030082740A1 (en) Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent
US7119069B2 (en) Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent
WO2002069885A2 (fr) Compositions anti-invasives et anti-angiogeniques et methodes de traitement de tumeurs cerebrales et d'autres pathologies
JP2002535372A (ja) プラスミノーゲンクリングル４領域フラグメントおよび利用法
AU2002247129A1 (en) Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent
WO2001042438A2 (fr) Leucolysine/mmp25/mt6-mmp
US20050164202A1 (en) Materials and methods relating to therapy and diagnosis using targeting of cells that express JPL polypeptides
US20040091887A1 (en) Mucroslysin and its gene

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20081007